Bull Harbor Capital LLC Acquires Shares of 5,077 Biogen Inc. $BIIB

Bull Harbor Capital LLC bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 1st quarter, Holdings Channel.com reports. The fund bought 5,077 shares of the biotechnology company’s stock, valued at approximately $931,000.

A number of other large investors have also modified their holdings of the business. Reflection Asset Management acquired a new stake in shares of Biogen in the 4th quarter valued at approximately $25,000. WPG Advisers LLC grew its holdings in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the period. First Horizon Corp acquired a new position in Biogen during the fourth quarter worth $30,000. WFA of San Diego LLC purchased a new position in Biogen in the second quarter worth $32,000. Finally, Root Financial Partners LLC lifted its holdings in Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 123 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q2 results exceeded expectations: Biogen reported approximately $2.74 billion in revenue, up 3.4% year over year and above the $2.46 billion consensus estimate. Adjusted EPS of $3.60 also topped forecasts near $2.94, supported by stronger rare-disease and newer-product sales. Biogen beats quarterly estimates as newer drugs fuel growth
• Positive Sentiment: Growth portfolio is offsetting legacy weakness: Revenue from Biogen’s Growth Portfolio rose 24% to about $1.06 billion, surpassing its legacy multiple sclerosis portfolio. The Apellis acquisition added sales from SYFOVRE and EMPAVELI, while products including SKYCLARYS and ZURZUVAE contributed to momentum. Biogen’s Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
• Positive Sentiment: Analyst sentiment improved: TD Cowen raised its price target to $225 and assigned a Buy rating, while Morgan Stanley lifted its target to $231 and maintained Equal Weight. Wedbush also raised its target to $215, and Piper Sandler reaffirmed its Buy rating. Analyst target updates
• Neutral Sentiment: 2026 outlook was updated: Biogen expects full-year non-GAAP EPS of $12 to $13 and mid-single-digit revenue growth. The revenue outlook benefits from the newer portfolio, but the EPS range is below the roughly $13.45 analyst consensus, partly reflecting acquisition-related costs. Biogen beats quarterly estimates as newer drugs fuel growth
• Negative Sentiment: Reported profitability deteriorated materially: GAAP net income fell to $97.5 million from $634.8 million a year earlier, while diluted EPS dropped to $0.66 from $4.33. Legacy multiple sclerosis sales also remained under pressure, and Leqembi sales narrowly missed expectations. Biogen profitability compression

Wall Street Analyst Weigh In

Several equities research analysts have commented on BIIB shares. Sanford C. Bernstein decreased their target price on shares of Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. Freedom Capital upgraded shares of Biogen from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. Mizuho decreased their price objective on shares of Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a report on Monday, June 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Biogen in a research report on Monday, June 22nd. Finally, Wall Street Zen raised shares of Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $223.36.

Biogen Trading Down 0.6%

Shares of BIIB stock opened at $207.93 on Friday. The stock has a market cap of $30.70 billion, a P/E ratio of 36.80 and a beta of 0.16. The company has a quick ratio of 2.41, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen Inc. has a fifty-two week low of $124.56 and a fifty-two week high of $219.72. The business has a fifty day simple moving average of $201.05 and a 200-day simple moving average of $190.52.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping the consensus estimate of $2.94 by $0.66. The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, analysts forecast that Biogen Inc. will post 12.38 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.